Carbapenem-Resistant Enterobacteriaceae Bacteremia in Pediatric Patients in Latin America and the Caribbean: A Systematic Review and Meta-Analysis
2024

Carbapenem-Resistant Enterobacteriaceae Infections in Children in Latin America

Sample size: 189 publication 10 minutes Evidence: moderate

Author Information

Author(s): Ruvinsky Silvina, Voto Carla, Roel Macarena, Portillo Victoria, Naranjo Zuñiga Gabriela, Ulloa-Gutierrez Rolando, Comandé Daniel, Ciapponi Agustín, Aboud Gabriela, Brizuela Martín, Bardach Ariel

Primary Institution: Hospital de Pediatría Dr. Juan P. Garrahan, Buenos Aires, Argentina

Hypothesis

What is the impact of carbapenem-resistant Enterobacteriaceae bloodstream infections in pediatric populations from Latin America and the Caribbean?

Conclusion

CRE bloodstream infections pose a significant threat to children with underlying conditions in Latin America and the Caribbean, leading to high morbidity and mortality.

Supporting Evidence

  • 14 studies involving 189 patients were analyzed.
  • Most cases were reported from Brazil, Argentina, Colombia, and Paraguay.
  • The median age of the patients was 35 months.
  • Key risk factors included immunocompromised status and invasive procedures.
  • The infections were predominantly hospital-acquired.
  • Klebsiella pneumoniae was the most common pathogen.
  • The mortality rate was found to be 34%.
  • Most patients received combination antimicrobial therapy for a median of 17 days.

Takeaway

This study shows that a type of bacteria that is hard to treat is making kids very sick in Latin America, especially those who are already sick.

Methodology

This systematic review followed Cochrane methodology and PRISMA/MOOSE guidelines, analyzing studies on hospitalized patients under 19 years with CRE bloodstream infections.

Potential Biases

Most studies had a low risk of bias, but challenges included determining whether cases were consecutive.

Limitations

The included studies often had a limited number of patients, and the clinical heterogeneity may affect the generalizability of results.

Participant Demographics

Patients had a median age of 35 months, with 56% being male and 62% immunocompromised.

Statistical Information

Confidence Interval

95% CI: 16–76 months

Digital Object Identifier (DOI)

10.3390/antibiotics13121117

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication